Attractive and sustainable shareholder returns are essential for biopharma companies, both for the medium and long term.
BCG has deep experience helping clients understand and optimize their particular value creation opportunities through total shareholder return analysis. That analytical process yielded BCG’s 2013 Biopharma Value Creators Report, which examines whether the recent resurgence in biopharma total shareholder return is a short-term spike or a more sustainable shift in value creation performance.
Although the sector is currently outperforming the market, biopharma companies’ performance continues to exhibit extreme variance. The report found that value creation is fundamentally a matter of individual company efforts, rather than “riding the rising tide” of an attractive sector. For management teams, success in value creation lies within their own control and depends on effective strategic choices and flawless execution.